Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.66 |
| ▸ | DRD3 | P35462 | 6/20 | 0.66 |
| ▸ | DRD4 | P21917 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8307788 | 0.82 | DRD2 (0.55) | DRD2DRD3HTR1A | |
| SCHEMBL1261038 | 0.81 | DRD2 (0.66) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL11981410 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL31681697 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL265580 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL3318587 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL3313069 | 0.79 | CHRM3 (0.77) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL14360233 | 0.79 | DRD2 (0.67) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL339581 | 0.79 | CHRM3 (0.77) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL3312525 | 0.79 | CHRM3 (0.77) | DRD2DRD3DRD4HTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100040545-A1 | RADIOLABELLING METHODS | HAMMERSMITH IMANET LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| WO-2008075043-A1 | RADIOLABELLING METHODS | HAMMERSMITH IMANET LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040545-A1 | RADIOLABELLING METHODS | NPSR1, SSTR3, SSTR5 | DRD2 246/4885DRD3 312/4885DRD4 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.